A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. N. Raju,M. A. Socinski,Tom Stinchcombe,L. S. Couch,Darren M. Kocs,Robert M. Jotte,Yue Wang,Jane Bromund,Martin D. Marciniak,Coleman K. Obasaju

A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

2016

R. N. Raju
M. A. Socinski
Tom Stinchcombe
L. S. Couch
Darren M. Kocs
Robert M. Jotte
Yue Wang
Jane Bromund
Martin D. Marciniak
Coleman K. Obasaju

e19050 Background: E is a selective, oral serine/threonine kinase inhibitor. PCb has shown promising clinical activity in two phase 2 trials of advanced NSCLC. This open-label, three-arm trial was ...

Keywords:

Quality of life
Kinase
Pemetrexed
Oncology
Docetaxel
Internal medicine
non-small cell lung cancer (NSCLC)
Pathology
Carboplatin
Enzastaurin
Medicine
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations